Proposed Agenda for 2020 IRLSSG Annual Meeting

Program Committee: Denise Sharon (USA), Aaro Salminen (Finland)


Target audience:
  1. Sleep specialists and internists interested in sleep disorders and in identifying and treating RLS with a more basic understanding of the disorder.
  2. RLS experts and researchers in the field.
  3.  Trainees interested in learning and developing the field.


Sunday June 14, 2020

8:30-8:45 Welcome and introductions (J. Winkelman, USA and A. O’Brian, USA)

Session 1. RLS basic science session (chair: A. Salminen, Finland)

8:45 - 9:00            Genetics of RLS update (B. Schormair, Germany)

9:00 - 9:15            Genetics of PLMS (E. Mignot, USA)

9:15 - 9:30            An update on molecular studies of RLS (F. Akcimen,  Canada) 

9:30 - 9:45            Probing the relationship between BTBD9 and MEIS1 in animal models of RLS (Y. Li, USA)

9:45-10:00           Sleep-related muscle activity is augmented by administration of serum from RLS patients in Btbd9 mutant mice. 
(S. Chikahisa, Japan)

10:00 - 10:15 Coffee break

Session 2. New developments in iron measurement and treatment in RLS (chair: R. Allen, USA)

10:15 -10:30        Johns Hopkins algorithm to iron measurements (C. Earley, USA)  

10:30 – 10:45      The clinical implementation of the quantitative transcranial sonography (D. Garcia-Borreguero, Spain)

10:45 -11:00        Intravenous Iron protocol for adolescents (D. Picchietti, USA)

Session 3. Young investigators (chair: Zak / Walters , USA)

11:00 – 12:15  up to 5 presentations 

12:15 – 13:15 Lunch

Session 4. RLS and PLMS: clinical aspects and treatment (chair: D. Sharon, UISA)

13:15 – 13:30      PLMS update (R. Allen, USA)

13:30 – 13:43      Dopaminergic treatment modulates functional brain connectivity in RLS (A. Stefani, Austria)

13:43 – 13:56      Iron therapy in pediatric RLS (L. DelRosso, USA)

13:56– 14:09       Update on Painful Willis-Ekbom disease: an unbearable and distinct form of restless legs? (E. Karroum, USA)

14:09– 14:22      Nearly 25% of RLS Patients Nationally Treated With Dopamine Agonists Are Taking Higher Doses Than The Maximum      Recommended By FDA And Expert Guidelines. (J. Winkelman, USA)

14:22 – 14:35      Testing the adenosine hypothesis:  a double-blind, cross-over, placebo-controlled trial with dipyridamole  (D. Garcia-Borreguero, Spain)

14:35 – 14:45      Epidural spinal electric stimulation in a severe case of RLS  (M. Manconi, Switzerland)

2:45– 3:00 Coffee

Session 5. Cooperative and IRLSSG endorsed projects (chair: J. Winkelman, USA)

3:00 – 3:30           EURLSSG and Highlights from the EURLSSG meeting (R. Silvestri, Italy)

3:30 – 3:40           RLS projects by RLS foundation (TBA) 

3:40 – 3:50           Animal models guideline (A. Salminen, Germany)

3:50 – 4:00           Diagnostic accuracy of RLS tools (R. Allen, USA)  

4:00 – 4:10           Opioid registry update (J. Winkelman, USA)

4:10 – 4:20           RSD project (L. DelRosso, USA)

4:20 – 4:30           Pediatric Task force (Art Walters, USA)

4:30 – 4:37           Update on AASM TF on Guidelines for treating RLS (A. Walters, USA)

4:37 – 4:45           A Call to Arms--breaking down silos and increasing interagency cooperation (R. Zak, USA)

4:45 – 5:00           Year in review  and future projects discussion (J Winkelman, USA)

5:15-6:00 Business meeting


Powered by Wild Apricot Membership Software